Analysis of immune response to overcome immune-escape of lung cancer

本研究的目的是评估非小细胞肺癌（NSCLC）患者克服肿瘤免疫逃逸机制的免疫应答。区域淋巴结中CD4+ CD25+ Foxp3+调节性T细胞比例较高是一个显著的不利预后因素，即使在淋巴结阴性的非小细胞肺癌患者中也是如此。与异质表达组相比，正常表达hla - I类与良好的预后相关。考虑HLA表达模式和调节性T细胞比例的临床意义，评估辅助免疫治疗的疗效是必要的。

The purpose of this study was to evaluate immune response in patients with non-small cell lung cancer (NSCLC) to overcome the tumor immune escape mechanism. The higher proportion of CD4+ CD25+ Foxp3+ regulatory T cells in the regional lymph node was a significant unfavorable prognostic factor, even in patients with node-negative NSCLC. The normal expression of HLA-class I was associated with a favorable prognosis in comparison with the heterogeneous expression group. It is necessary to evaluate the efficacy of adjuvant immunotherapy in consideration of clinical significance of the HLA expression pattern and the proportion of regulatory T cells.